* Note: Prices are in Million (M) USD.
Description:
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
These criteria used Company's Cash, EBITDA and Debt balance to determines its fair value:
Cash : $2,627 M
Debt : $1,080 M
EBITDA : $-122 M
Since Ebitda is less than 0, 0 points assigned.
This criteria used industry in which company operates:
Sector: LIFE SCIENCES
Industry: PHARMACEUTICAL PREPARATIONS
Based on industry, 3 points assigned.
This criteria used Company's Price To Earning (P/E) Ratio to determines its fair value:
Forward PE Ratio: 44.65
Since Forward PE Ratio is greater than 35, 0 point assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Average Free Cash Flow: $-1,404 M
Average Revenue: $839 M
Revenue Converted To Free Cash FLow(%): -167%
Since Free Cash Flow (FCF) to Revenue percentage is negative, 0 point assigned.
This criteria used company's growth potential to calculate its fair value:
Latest Revenue (2024-12-31): $3,810 M
Revenue 4 Years Ago (2020-12-31): $309 M
Last 5 Years Average Revenue Growth: 227%
Since Revenue Growth is greater than 20, 5 points assigned.
This criteria used Company's ability to buy back its own share:
Latest Share Count (2024-12-31): $105 M
Share Count 5 Years Ago (2020-12-31): $83 M
Company is not buying back its own shares, 0 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Next Year Earnings Per Share (EPS): $11.06
Trailing 12-Month Earnings Per Share (EPS): $2.33
Average Earnings Per Share (EPS): $6.70
Dividend Per Share (DPS): $0
Payout Ratio: 0%
Dividend Yield: 0%
Since Dividend Per Share is less than or equal to 0, 0 point assigned.
Since Dividend Yield is less than 1, 0 point assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Average ROE: -41%
Since Average ROE is negative, 0 point assigned.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $299
52-Week Low: $156
Threshold Price (15% Above 52-Week Low): $179
Since Current price is not within 15% threshold, 0 point assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $33,276 M
Since Market Cap is between 10B - 100B, 2 points assigned.
% Exposure to Total Portfolio
Based on the market cap, we recommend do not exceed 3% exposure of Total Portfolio.
Value-Trade has assigned 10 points to above BeiGene, Ltd. (ONC) stock.
Value-Trades has assined P/E value 12. Since an average (Current Year EPS + Next Year EPS) earning per share is $6.6973.
The fair value of BeiGene, Ltd. (ONC) stock should be (12 x $6.6973) = $80.37
